|
|
Unidos Venceremos!
Clique
aqui
para imprimir esta página para sua referência e consulta.
HEP
C INFO - http://hepatitis-central.com
Viragen Updates Progress; E' Newsletter Released On Web Site
PLANTATION, Fla., Oct. 5 /PRNewswire/ -- Viragen, Inc. (Amex: VRA) today
released its latest progress report through an "electronic"
newsletter viewable on the company's Web site at: www.viragen.com.
The newsletter highlights Viragen's accomplishments in 2000 including:
* Progression of Omniferon(TM) Through Phase II Clinical Trials
* $60 Million Dollar Financing By Ladenberg Thalmann & Co. Inc.
* VRA Commences Trading On American Stock Exchange
* Agreement To Develop Cancer Vaccine With U.K.'s CRCT
* NIH Grants Exclusive Worldwide License For New Cancer Therapy
* Collaboration With Cryolife On Cancer Therapeutic Project
* Collaboration With Valentis To Develop PEGylated Omniferon
* Agreement With Zonagen To Study Genital Herpes Treatment
* Signing Of Space Act Agreement With NASA
* Annual Meeting Hosted By American Stock Exchange
Viragen, Inc. is engaged in the research, development and manufacture
of immunomodulatory therapeutic products, including natural human interferon
and human monoclonal antibodies for the treatment of various life-threatening
and debilitating diseases, such as hepatitis B & C, multiple sclerosis,
genital herpes and cancer.
Produced in its Scottish facility, Viragen's lead product, Omniferon(TM),
is currently in Phase II clinical trials in Europe for hepatitis C, a
disease estimated to afflict tens of millions worldwide. Viragen has a
collaborative agreement with the Common Services Agency of the United
Kingdom; preferential access to the white blood cells collected by the
German Red Cross and America's Blood Centers; and a white blood cell agreement
with the American Red Cross.
Viragen and Valentis, Inc. are developing a PEGylated version of Omniferon
in order to reduce the drug's dosing frequency and improve its efficacy
and side-effect profile. PEGylation has been shown to improve a drug's
performance by extending the time a drug remains in the body. Viragen
is also collaborating with Zonagen, Inc. in studying a topically applied
enhanced formulation of Omniferon for the treatment of genital herpes,
a sexually transmitted disease infecting one out of every five Americans
aged 12 or older. Viragen has also entered into a Space Act Agreement
with NASA's Johnson Space Center to test micro-gravity bioreactors.
Viragen's Oncology Project includes a collaboration with Memorial Sloan-Kettering
Cancer Center for the development of a human monoclonal antibody for the
treatment of melanoma and other cancers. Viragen is also collaborating
with the U.K.'s Cancer Research Campaign Technology to develop a cancer
vaccine therapy for the treatment of several indications including breast,
ovarian and colorectal cancers. Viragen is involved in an additional project
with Cryolife, Inc. to assess the potential of attaching anti-cancer proteins
to human monoclonal antibodies and delivering them to specific tumors.
For more information, please visit our Web site at www.viragen.com
or contact "Company News On Call" at 1-800-758-5804, followed
by extension 116574.
This foregoing press release contains forward-looking statements that
can be identified by such terminology such as "expects," "potential,"
"suggests," "may," "will," or similar expressions.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results to be materially different
from any future results, performance or achievements expressed or implied
by such statements. In particular, management's expectations regarding
future research development results could be affected by, among other
things, uncertainties relating to clinical trials and product development;
unexpected regulatory delays or government regulation generally; the Company's
ability to obtain or maintain patent and other proprietary intellectual
property protection; and competition in general.
SOURCE Viragen, Inc.
CO: Viragen, Inc.; Valentis, Inc.; Ladenberg Thalmann & Co. Inc.;
Zonagen,Inc.; NASA; Johnson Space Center; Memorial Sloan-Kettering Cancer
Center; Cancer Research Campaign Technology
ST: Florida, United Kingdom
|
